A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Public ClinicalTrials.gov record NCT05529316. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicohort, Open Label, Phase 2 Study of Botensilimab (AGEN1181) for Treatment of Advanced Melanoma Refractory to Prior Checkpoint Inhibitor Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy.
Study identification
- NCT ID
- NCT05529316
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2022
- Primary completion
- Jan 31, 2028
- Completion
- Jan 31, 2028
- Last update posted
- Jan 15, 2026
2022 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scottsdale Healthcare Hospitals DBA HonorHealth | Scottsdale | Arizona | 85258 | — |
| Virginia K. Crosson Cancer Center at St. Jude Medical Center | Fullerton | California | 92835 | — |
| Providence Saint John's Health Center | Santa Monica | California | 90404 | — |
| Yale University School of Medicine - Yale Cancer Center | New Haven | Connecticut | 06520-8028 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20057 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
Recently updated Advanced Melanoma trials
Other public records listing Advanced Melanoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07634380: Sitagliptin With Pembro in RCC and Melanoma Recruiting
- NCT05629546: Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors Recruiting
- NCT02965716: Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Active, not recruiting
- NCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] Recruiting
- NCT06594991: A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma Recruiting
- NCT06697301: Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05529316, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 15, 2026 · Synced Jul 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05529316 live on ClinicalTrials.gov.